Absolute risk of progression of MGUS to myeloma or related disorders based on the serum FLC ratio
. | Risk based on FLC (kappa-lambda) ratio using the current diagnostic reference range . | . | Risk based on increasingly abnormal FLC (kappa-lambda) ratio . | . | . | |||
|---|---|---|---|---|---|---|---|---|
. | Normal ratio 0.26-1.65* . | Abnormal ratio < 0.26 or > 1.65† . | FLC ratio 0.25-4‡ . | FLC ratio 0.125-0.25 or 4-8§ . | FLC ratio < 0.125 or > 8∥ . | |||
| Absolute risk of progression, % of patients (95% CI) | ||||||||
| Time of follow-up | ||||||||
| 5 y | 2.5 (1.3-3.8) | 8 (4.8-11) | 3.1 (1.9-4.4) | 9.4 (2.4-15.9) | 13.5 (4.3-22.5) | |||
| 10 y | 5.3 (3.2-7.4) | 16.7 (11.4-21.7) | 6.4 (4.4-8.4) | 19.3 (8.5-31.3) | 31.7 (13.5-46.1) | |||
| 15 y | 6.6 (4-9.8) | 29.9 (21.1-37.8) | 9.6 (6.5-12.6) | 42.3 (20.1-60.4) | 47.3 (18.6-67.1) | |||
| 20 y | 12.6 (4.5-20.7) | 35 (23.6-45) | 15.8 (8.5-22.7) | 42.3 (20.1-67.2) | 60.5 (19.3-82.7) | |||
| Cumulative annual rate of progression, %/y | 0.6 | 1.8 | 0.8 | 2 | 3 | |||
| Cumulative annual rate of progression, after adjusting for competing risk of death, %/y | 0.3 | 0.8 | 0.4 | 1 | 1.3 | |||
. | Risk based on FLC (kappa-lambda) ratio using the current diagnostic reference range . | . | Risk based on increasingly abnormal FLC (kappa-lambda) ratio . | . | . | |||
|---|---|---|---|---|---|---|---|---|
. | Normal ratio 0.26-1.65* . | Abnormal ratio < 0.26 or > 1.65† . | FLC ratio 0.25-4‡ . | FLC ratio 0.125-0.25 or 4-8§ . | FLC ratio < 0.125 or > 8∥ . | |||
| Absolute risk of progression, % of patients (95% CI) | ||||||||
| Time of follow-up | ||||||||
| 5 y | 2.5 (1.3-3.8) | 8 (4.8-11) | 3.1 (1.9-4.4) | 9.4 (2.4-15.9) | 13.5 (4.3-22.5) | |||
| 10 y | 5.3 (3.2-7.4) | 16.7 (11.4-21.7) | 6.4 (4.4-8.4) | 19.3 (8.5-31.3) | 31.7 (13.5-46.1) | |||
| 15 y | 6.6 (4-9.8) | 29.9 (21.1-37.8) | 9.6 (6.5-12.6) | 42.3 (20.1-60.4) | 47.3 (18.6-67.1) | |||
| 20 y | 12.6 (4.5-20.7) | 35 (23.6-45) | 15.8 (8.5-22.7) | 42.3 (20.1-67.2) | 60.5 (19.3-82.7) | |||
| Cumulative annual rate of progression, %/y | 0.6 | 1.8 | 0.8 | 2 | 3 | |||
| Cumulative annual rate of progression, after adjusting for competing risk of death, %/y | 0.3 | 0.8 | 0.4 | 1 | 1.3 | |||